{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:45:07Z","timestamp":1794617107442,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101838"],"award-info":[{"award-number":["82101838"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203367"],"award-info":[{"award-number":["82203367"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) metastasis has emerged as a leading cause of mortality globally. Owing to the distinctive looping structure, circular RNA has become an ideal biological tumor marker. Here we investigate the mechanism and function of circular RNA, specifically circCNOT6L, on PCa metastasis. A loss-of-function assay was conducted in vitro to assess the impact of circCNOT6L on cancer cell proliferation, migration, invasion and ferroptosis. In addition, a xenograft mouse model was used to elucidate the influence of circCNOT6L on subcutaneous tumor xenograft and lung metastasis. Biochemical experiments elucidated the molecular mechanism by which circCNOT6L promotes malignant progression in PCa cells by modulating ferroptosis. Moreover, the combination of circCNOT6L-si and a ferroptosis activator was tested in organoids to evaluate their potential as suppressors of tumorigenesis. The novel circular RNA, circCNOT6L, was highly expressed in both PCa metastatic tissues and cells. circCNOT6L suppression resulted in a notable inhibition in PCa cell migration, invasion and ferroptosis in vitro. Furthermore, circCNOT6L inhibition hindered the growth and metastasis of mouse xenografts. Mechanistically, circCNOT6L, generated by the RNA-binding protein EIF4A3, competes with miR-143-5p for binding, thereby facilitating SRSF2-dependent splicing of SLC7A11 precursor RNA. This process inhibited ferroptosis in PCa cells and promoted PCa progression. Finally, inhibiting circCNOT6L overexpression in combination with the ferroptosis activator (erastin) significantly suppressed the viability of PCa-derived organoids. In conclusion, in the present study, we found that circCNOT6L induced by EIF4A3 through the SRSF2\u2013SLC7A11 axis effectively inhibits ferroptosis, which in turn promotes malignant progression of PCa.<\/jats:p>","DOI":"10.1038\/s12276-025-01540-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T03:36:33Z","timestamp":1759116993000},"page":"2106-2120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["CircCNOT6L modulates alternative splicing of SLC7A11 via splicing factor SRSF2 to confer ferroptosis resistance and promote metastasis in prostate cancer"],"prefix":"10.1038","volume":"57","author":[{"given":"Ji","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maskey","family":"Niraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaitiaji","family":"Kadier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changcheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-8035","authenticated-orcid":false,"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4652-6828","authenticated-orcid":false,"given":"Shiyu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-3940","authenticated-orcid":false,"given":"Xudong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"1540_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"1540_CR2","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"1540_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrurol.2016.175","volume":"14","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian, J. J. et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol. 14, 15\u201325 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"1540_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","volume":"530","author":"J Kang","year":"2022","unstructured":"Kang, J. et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 530, 156\u2013169 (2022).","journal-title":"Cancer Lett."},{"key":"1540_CR5","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.7150\/thno.33972","volume":"9","author":"DJ Lv","year":"2019","unstructured":"Lv, D. J. et al. HMGB1 promotes prostate cancer development and metastasis by interacting with Brahma-related gene 1 and activating the Akt signaling pathway. Theranostics 9, 5166\u20135182 (2019).","journal-title":"Theranostics"},{"key":"1540_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2890","volume":"32","author":"WR Jeck","year":"2014","unstructured":"Jeck, W. R. & Sharpless, N. E. Detecting and characterizing circular RNAs. Nat. Biotechnol. 32, 453\u2013461 (2014).","journal-title":"Nat. Biotechnol."},{"key":"1540_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/1878-0261.12468","volume":"13","author":"L Verduci","year":"2019","unstructured":"Verduci, L., Strano, S., Yarden, Y. & Blandino, G. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol. Oncol. 13, 669\u2013680 (2019).","journal-title":"Mol. Oncol."},{"key":"1540_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1096\/fasebj.7.1.7678559","volume":"7","author":"C Cocquerelle","year":"1993","unstructured":"Cocquerelle, C., Mascrez, B., H\u00e9tuin, D. & Bailleul, B. Mis-splicing yields circular RNA molecules. FASEB J. 7, 155\u2013160 (1993).","journal-title":"FASEB J."},{"key":"1540_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.4161\/cc.24363","volume":"12","author":"V Edmond","year":"2013","unstructured":"Edmond, V. et al. A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors. Cell Cycle 12, 1267\u20131278 (2013).","journal-title":"Cell Cycle"},{"key":"1540_CR10","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo, L. et al. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood 136, 1851\u20131862 (2020).","journal-title":"Blood"},{"key":"1540_CR11","doi-asserted-by":"publisher","unstructured":"K\u0119dzierska, H. et al. Decreased expression of SRSF2 splicing factor inhibits apoptotic pathways in renal cancer. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms17101598 (2016).","DOI":"10.3390\/ijms17101598"},{"key":"1540_CR12","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1038\/s41418-021-00779-y","volume":"28","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. Mirtronic miR-4646-5p promotes gastric cancer metastasis by regulating ABHD16A and metabolite lysophosphatidylserines. Cell Death Differ. 28, 2708\u20132727 (2021).","journal-title":"Cell Death Differ."},{"key":"1540_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273\u2013285 (2017).","journal-title":"Cell"},{"key":"1540_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"1540_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.10.011","volume":"32","author":"J Zheng","year":"2020","unstructured":"Zheng, J. & Conrad, M. The metabolic underpinnings of ferroptosis. Cell Metab. 32, 920\u2013937 (2020).","journal-title":"Cell Metab."},{"key":"1540_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00726-011-0867-5","volume":"42","author":"M Conrad","year":"2012","unstructured":"Conrad, M. & Sato, H. The oxidative stress-inducible cystine\/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids 42, 231\u2013246 (2012).","journal-title":"Amino Acids"},{"key":"1540_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","volume":"38","author":"P Koppula","year":"2018","unstructured":"Koppula, P., Zhang, Y., Zhuang, L. & Gan, B. Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 38, 12 (2018).","journal-title":"Cancer Commun."},{"key":"1540_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc776","volume":"2","author":"FH Igney","year":"2002","unstructured":"Igney, F. H. & Krammer, P. H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277\u2013288 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"1540_CR19","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun, R. et al. Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res. 83, 3192\u20133204 (2023).","journal-title":"Cancer Res."},{"key":"1540_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100985","volume":"70","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist. Updat. 70, 100985 (2023).","journal-title":"Drug Resist. Updat."},{"key":"1540_CR21","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1073\/pnas.1905384117","volume":"117","author":"EC Hsu","year":"2020","unstructured":"Hsu, E. C. et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc. Natl Acad. Sci. USA 117, 2032\u20132042 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1540_CR22","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1200\/JCO.2016.69.9918","volume":"35","author":"D Dalela","year":"2017","unstructured":"Dalela, D. et al. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: development and internal validation of a multivariable prognostic model. J. Clin. Oncol. 35, 1982\u20131990 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1540_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0321-5","volume":"14","author":"Z Su","year":"2015","unstructured":"Su, Z., Yang, Z., Xu, Y., Chen, Y. & Yu, Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol. Cancer 14, 48 (2015).","journal-title":"Mol. Cancer"},{"key":"1540_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27452-9","volume":"12","author":"F Yao","year":"2021","unstructured":"Yao, F. et al. A targetable LIFR-NF-\u03baB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat. Commun. 12, 7333 (2021).","journal-title":"Nat. Commun."},{"key":"1540_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01286-3","volume":"19","author":"WY Zhou","year":"2020","unstructured":"Zhou, W. Y. et al. Circular RNA: metabolism, functions and interactions with proteins. Mol. Cancer 19, 172 (2020).","journal-title":"Mol. Cancer"},{"key":"1540_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1135-7","volume":"19","author":"M Lei","year":"2020","unstructured":"Lei, M., Zheng, G., Ning, Q., Zheng, J. & Dong, D. Translation and functional roles of circular RNAs in human cancer. Mol. Cancer 19, 30 (2020).","journal-title":"Mol. Cancer"},{"key":"1540_CR27","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2147\/OTT.S293180","volume":"14","author":"Y Huang","year":"2021","unstructured":"Huang, Y., Jiang, L. & Wei, G. Circ_0006168 promotes the migration, invasion and proliferation of esophageal squamous cell carcinoma cells via miR-516b-5p-dependent regulation of XBP1. Onco Targets Ther. 14, 2475\u20132488 (2021).","journal-title":"Onco Targets Ther."},{"key":"1540_CR28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/15384101.2021.1930357","volume":"20","author":"T Wang","year":"2021","unstructured":"Wang, T. et al. Blocking hsa_circ_0006168 suppresses cell proliferation and motility of human glioblastoma cells by regulating hsa_circ_0006168\/miR-628-5p\/IGF1R ceRNA axis. Cell Cycle 20, 1181\u20131194 (2021).","journal-title":"Cell Cycle"},{"key":"1540_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3892\/ol.2022.13268","volume":"23","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. miR-143-5p suppresses breast cancer progression by targeting the HIF-1\u03b1-related GLUT1 pathway. Oncol. Lett. 23, 147 (2022).","journal-title":"Oncol. Lett."},{"key":"1540_CR30","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1159\/000479903","volume":"42","author":"M He","year":"2017","unstructured":"He, M. et al. MiR-143-5p deficiency triggers EMT and metastasis by targeting HIF-1\u03b1 in gallbladder cancer. Cell Physiol. Biochem. 42, 2078\u20132092 (2017).","journal-title":"Cell Physiol. Biochem."},{"key":"1540_CR31","doi-asserted-by":"publisher","first-page":"12727","DOI":"10.1002\/jcp.27893","volume":"234","author":"DC Liu","year":"2019","unstructured":"Liu, D. C. et al. Long noncoding RNA LEF1-AS1 silencing suppresses the initiation and development of prostate cancer by acting as a molecular sponge of miR-330-5p via LEF1 repression. J. Cell Physiol. 234, 12727\u201312744 (2019).","journal-title":"J. Cell Physiol."},{"key":"1540_CR32","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1158\/0008-5472.CAN-16-1919","volume":"77","author":"C Luo","year":"2017","unstructured":"Luo, C. et al. SRSF2 regulates alternative splicing to drive hepatocellular carcinoma development. Cancer Res. 77, 1168\u20131178 (2017).","journal-title":"Cancer Res."},{"key":"1540_CR33","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41375-018-0152-7","volume":"32","author":"Y Liang","year":"2018","unstructured":"Liang, Y. et al. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia 32, 2659\u20132671 (2018).","journal-title":"Leukemia"},{"key":"1540_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).","journal-title":"Cell Death Dis."},{"key":"1540_CR35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","volume":"9","author":"X Lang","year":"2019","unstructured":"Lang, X. et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9, 1673\u20131685 (2019).","journal-title":"Cancer Discov."},{"key":"1540_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106148","volume":"178","author":"MT Chang","year":"2022","unstructured":"Chang, M. T., Tsai, L. C., Nakagawa-Goto, K., Lee, K. H. & Shyur, L. F. Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming. Pharm. Res. 178, 106148 (2022).","journal-title":"Pharm. Res."},{"key":"1540_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41388-022-02537-x","volume":"42","author":"D Li","year":"2023","unstructured":"Li, D. et al. CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1. Oncogene 42, 83\u201398 (2023).","journal-title":"Oncogene"},{"key":"1540_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25354-4","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat. Commun. 12, 5103 (2021).","journal-title":"Nat. Commun."},{"key":"1540_CR39","doi-asserted-by":"publisher","unstructured":"Schwab, A. et al. Zeb1 mediates EMT\/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression and phospholipid composition. Nat. Cell Biol. https:\/\/doi.org\/10.1038\/s41556-024-01464-1 (2024).","DOI":"10.1038\/s41556-024-01464-1"},{"key":"1540_CR40","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1039\/D0MH01992E","volume":"8","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. PSMA-targeted arsenic nanosheets: a platform for prostate cancer therapy via ferroptosis and ATM deficiency-triggered chemosensitization. Mater. Horiz. 8, 2216\u20132229 (2021).","journal-title":"Mater. Horiz."},{"key":"1540_CR41","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani, A. et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 81, 1583\u20131594 (2021).","journal-title":"Cancer Res."},{"key":"1540_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29018-9","volume":"13","author":"M Wu","year":"2022","unstructured":"Wu, M. et al. Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nat. Commun. 13, 1371 (2022).","journal-title":"Nat. Commun."},{"key":"1540_CR43","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1158\/0008-5472.CAN-21-3230","volume":"82","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Mitochondrial calcium uniporter drives metastasis and confers a targetable cystine dependency in pancreatic cancer. Cancer Res. 82, 2254\u20132268 (2022).","journal-title":"Cancer Res."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01540-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T03:44:32Z","timestamp":1759981472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01540-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01540-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3970046\/v1","asserted-by":"object"}]},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have read the journal\u2019s position on issues involved in ethical publication, and all authors have approved the final version of the paper. The paper has been edited by Bullet Rewriters.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}